ABSTRACT
Objective To investigate the clinical value of ranibizumab combined with fundus laser in the treatment of macular edema secondary to branch retinal vein occlusion (RVO).Methods From June 2016 to June 2017,98 patients with RVO secondary macular edema in the People's Hospital of Linfen were randomly divided into three groups according to the digital table:A group (30 cases) treated with simple fundus laser,B group (33 cases) treated with intravitreal injection of ranibizumab,C group(35 cases) treated with fundus laser combined with intravitreal injection of ranibizumab.The best corrected visual acuity (BCVA),macular fovea thickness (CMT),leakage rate,injection times and complications were compared among the three groups before and after treatment.Results At 3,6,9,12 months after treatment,the BCVA among A group,B group and C group had statistically significant differences (F=4.165,5.021,6.954,all P ＜0.05),and the BCVA of C group was better than that of B group,the BCVA of B group was better than that of A group (t =3.985,3.852,3.779,4.021,3.624,3.729,all P ＜0.05).There were statistically significant differences in CMT among A group,B group and C group at 3 months and 6 months after treatment (F =6.772,14.025,all P ＜ 0.05),and the CMT of C group was less than that of B group,the CMT of B group was less than that of A group (t =5.325,11.251,3.992,6.895,all P ＜ 0.05).At 6 months after treatment,the leakage rate in C group (2.86％) was lower than that in B group (18.18％),the leakage rate in B group was lower than that in A group (23.33％) (x2 =6.148,P ＜ 0.05).The injection times of ranibizumab in B group was (2.93 ± 1.52),which was significantly less than that in C group (2.00 ± 0.56) (t =3.349,P ＜ 0.05).Conclusion The short-term clinical effect of ranibizumab combined with fundus laser in the treatment of macular edema secondary to RVO is better than laser therapy and ranibizumab alone,and the injection times of ranibizumab can be reduced.
ABSTRACT
Objective@#To investigate the clinical value of ranibizumab combined with fundus laser in the treatment of macular edema secondary to branch retinal vein occlusion(RVO).@*Methods@#From June 2016 to June 2017, 98 patients with RVO secondary macular edema in the People's Hospital of Linfen were randomly divided into three groups according to the digital table: A group (30 cases) treated with simple fundus laser, B group (33 cases) treated with intravitreal injection of ranibizumab, C group(35 cases) treated with fundus laser combined with intravitreal injection of ranibizumab.The best corrected visual acuity(BCVA), macular fovea thickness(CMT), leakage rate, injection times and complications were compared among the three groups before and after treatment.@*Results@#At 3, 6, 9, 12 months after treatment, the BCVA among A group, B group and C group had statistically significant differences (F=4.165, 5.021, 6.954, all P<0.05), and the BCVA of C group was better than that of B group, the BCVA of B group was better than that of A group (t=3.985, 3.852, 3.779, 4.021, 3.624, 3.729, all P<0.05). There were statistically significant differences in CMT among A group, B group and C group at 3 months and 6 months after treatment (F=6.772, 14.025, all P<0.05), and the CMT of C group was less than that of B group, the CMT of B group was less than that of A group (t=5.325, 11.251, 3.992, 6.895, all P<0.05). At 6 months after treatment, the leakage rate in C group (2.86%) was lower than that in B group (18.18%), the leakage rate in B group was lower than that in A group (23.33%) (χ2=6.148, P<0.05). The injection times of ranibizumab in B group was (2.93±1.52), which was significantly less than that in C group (2.00±0.56)(t=3.349, P<0.05).@*Conclusion@#The short-term clinical effect of ranibizumab combined with fundus laser in the treatment of macular edema secondary to RVO is better than laser therapy and ranibizumab alone, and the injection times of ranibizumab can be reduced.